Munich Cancer Registry

Munich Cancer Registry at Munich Cancer Center
Marchioninistr. 15
Munich, 81377
Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Baseline statistics

P-NET: Pancr. neuroend. tumor

Year of diagnosis	1998-2013
Patients	328
Diseases	328
Creation date	05/19/2015
Export date	12/30/2014
Population	4.64 m

BERLIN

GERMANY

BAVARIA

MUNICH

http://www.tumorregister-muenchen.de/en/facts/base/base_hPNETE.pdf

Global Statements about the statistics on the Internet −
Baseline Statistics (grey button ⬜), **Survival** (red button 🟥)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.64 million inhabitants, account for the frequency of cancer diseases[##] and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases[###] are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, May 2015

[#]   Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2014 are incorporated into these analyses.

[##]   Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.

[###]   DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.

Topography codes (ICD-O-3 2000) used for specifying cancer site

Code	Description
C25.-	Malignant neoplasm of pancreas
C25.0	Head of pancreas
C25.1	Body of pancreas
C25.2	Tail of pancreas
C25.3	Pancreatic duct
C25.4	Endocrine pancreas
C25.7	Other parts of pancreas
C25.8	Overlapping lesion of pancreas
C25.9	Pancreas, unspecified

`... if additionally existing any of ...`

Morphology codes (ICD-O-3 2011) used for specifying cancer site

Code	Description
8013/3	Large cell neuroendocrine carcinoma
8041/3	Small cell carcinoma, NOS
8150/3	Pancreatic endocrine tumor, malignant
8151/3	Insulinoma, malignant
8152/3	Glucagonoma, malignant
8153/3	Gastrinoma, malignant
8155/3	Vipoma, malignant
8156/3	Somatostatinoma, malignant
8240/3	Carcinoid tumor, NOS
8241/3	Enterochromaffin cell carcinoid
8246/3	Neuroendocrine carcinoma, NOS
8249/3	Atypical carcinoid tumor

Reference:

Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System 4th edition, IARC, Lyon (2010).

INCIDENCE

Table 1

Patient cohorts by year of diagnosis including
multiple primaries, and with proportion of deaths and active follow-up

Year of diagnosis	Cases n	Prop. mult. primaries %	Prop. deaths %	Prop. actively followed %	
1998	9	22.2	77.8	100.0	
1999	7	28.6	42.9	85.7	
2000	5		60.0	100.0	
2001	4	75.0	50.0	100.0	
2002	13	15.4	69.2	100.0	#
2003	14	28.6	64.3	92.9	
2004	11	27.3	63.6	100.0	
2005	18	27.8	50.0	100.0	
2006	14	28.6	64.3	100.0	
2007	26	26.9	46.2	88.5	# ##
2008	18	27.8	38.9	83.3	
2009	26	15.4	73.1	96.2	
2010	39	38.5	46.2	71.8	
2011	42	19.0	33.3	64.3	
2012	48	27.1	16.7	68.8	
2013	34	29.4	20.6	100.0	###
1998–2013	328	26.5	43.6	84.8	

Due to the pathohistological classification of the tumor and the lack of information on morphology on the death certificates, the proportion of DCO cases can not be determined.

\#   The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

\##   Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

\###   Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

Table 1a

Patient cohorts by year of diagnosis and gender
including DCO cases

Year of diagnosis	All n	Males n	Females n	Prop. males %
1998	9	6	3	66.7
1999	7	6	1	85.7
2000	5	3	2	60.0
2001	4	2	2	50.0
2002	13	10	3	76.9
2003	14	6	8	42.9
2004	11	9	2	81.8
2005	18	10	8	55.6
2006	14	12	2	85.7
2007	26	17	9	65.4
2008	18	7	11	38.9
2009	26	14	12	53.8
2010	39	22	17	56.4
2011	42	22	20	52.4
2012	48	26	22	54.2
2013	34	14	20	41.2
1998-2013	328	186	142	56.7

Table 2

Incidence measures by year of diagnosis and gender including DCO cases
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.64 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	6	3	0.5	0.3	0.3	0.2	0.5	0.2	0.6	0.3
1999	6	1	0.5	0.1	0.4	0.0	0.5	0.1	0.5	0.1
2000	3	2	0.3	0.2	0.2	0.1	0.2	0.1	0.3	0.1
2001	2	2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1
2002	10	3	0.5	0.2	0.4	0.0	0.5	0.1	0.5	0.1
2003	6	8	0.3	0.4	0.2	0.3	0.3	0.4	0.3	0.4
2004	9	2	0.5	0.1	0.3	0.1	0.4	0.1	0.5	0.1
2005	10	8	0.5	0.4	0.3	0.2	0.4	0.3	0.5	0.3
2006	12	2	0.6	0.1	0.4	0.0	0.5	0.1	0.6	0.1
2007	17	9	0.8	0.4	0.5	0.2	0.7	0.3	0.7	0.4
2008	7	11	0.3	0.5	0.2	0.3	0.3	0.3	0.3	0.4
2009	14	12	0.6	0.5	0.4	0.2	0.5	0.4	0.6	0.4
2010	22	17	1.0	0.7	0.5	0.4	0.8	0.6	0.9	0.7
2011	22	20	1.0	0.8	0.6	0.5	0.8	0.6	0.9	0.7
2012	26	22	1.1	0.9	0.6	0.5	0.9	0.7	1.0	0.8
2013	14	20	0.6	0.8	0.3	0.5	0.4	0.6	0.6	0.7
1998-2013	186	142	0.6	0.5	0.4	0.3	0.5	0.3	0.6	0.4

The computation of the incidence measures includes all primaries, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (All)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	9	59.0	14.1	28.2	77.8	28.2	57.0	62.0	63.4	77.8
1999	7	58.7	15.0	27.6	72.2	27.6	53.5	62.3	67.7	72.2
2000	5	57.9	17.5	33.1	74.8	33.1	50.0	57.5	73.9	74.8
2001	4	56.6	12.2	38.6	65.1	38.6	49.3	61.3	63.8	65.1
2002	13	59.9	15.2	36.0	87.6	42.3	49.0	64.3	66.3	83.5
2003	14	58.2	11.1	37.1	77.0	46.6	50.2	56.5	67.3	74.6
2004	11	60.7	12.2	40.8	77.5	46.1	48.3	62.3	74.1	76.2
2005	18	62.8	13.2	36.2	83.5	42.1	55.6	66.4	70.4	77.5
2006	14	58.6	19.3	16.8	78.1	29.1	42.3	64.8	73.1	76.8
2007	26	59.2	11.8	35.3	82.3	44.9	51.2	59.0	69.1	71.5
2008	18	57.6	18.3	23.8	81.2	28.0	47.1	56.8	74.8	79.4
2009	26	66.2	13.2	27.9	85.0	50.2	59.9	67.6	75.3	84.3
2010	39	63.0	12.5	37.5	83.6	46.3	52.5	62.4	74.6	79.0
2011	42	61.9	12.2	34.6	80.5	43.7	52.0	64.6	70.9	74.4
2012	48	63.8	14.6	27.7	101	42.3	57.4	66.8	72.1	77.5
2013	34	67.3	10.6	42.2	86.3	51.1	63.6	68.9	75.4	78.4
1998-2013	328	62.1	13.6	16.8	101	42.8	52.4	64.3	71.9	77.5

Table 3a

Age distribution parameters by year of diagnosis (MALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	6	66.0	7.1	58.9	77.8	58.9	62.0	63.0	71.5	77.8
1999	6	58.5	16.4	27.6	72.2	27.6	53.5	64.9	67.7	72.2
2000	3	60.5	12.2	50.0	73.9	50.0	50.0	57.5	73.9	73.9
2001	2	61.3	1.7	60.1	62.5	60.1	60.1	61.3	62.5	62.5
2002	10	54.2	11.0	36.0	66.8	39.2	46.4	53.1	65.1	66.2
2003	6	63.2	10.4	48.1	77.0	48.1	55.1	64.9	69.2	77.0
2004	9	62.7	12.4	40.8	77.5	40.8	58.7	63.0	74.1	77.5
2005	10	65.3	14.4	36.2	83.5	41.2	62.8	67.8	74.9	80.5
2006	12	56.9	20.5	16.8	78.1	29.1	40.4	60.8	73.9	76.8
2007	17	57.9	9.6	35.3	71.0	44.9	52.9	57.6	64.9	69.8
2008	7	51.0	17.7	28.0	79.4	28.0	35.4	49.3	67.5	79.4
2009	14	65.4	10.7	46.7	84.3	50.2	60.3	67.2	68.9	78.7
2010	22	65.6	11.0	44.6	83.6	52.8	58.0	64.4	74.6	79.0
2011	22	62.2	10.1	43.8	80.5	48.4	52.0	63.5	69.8	73.1
2012	26	63.1	14.3	27.7	84.2	42.1	59.2	68.4	71.2	76.8
2013	14	69.5	10.0	46.3	81.8	51.5	67.7	71.2	76.3	78.4
1998-2013	186	62.1	12.9	16.8	84.3	44.9	53.5	64.1	71.1	77.0

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	3	45.0	15.0	28.2	57.0	28.2	28.2	49.7	57.0	57.0
1999	1	59.7		59.7	59.7	59.7	59.7	59.7	59.7	59.7
2000	2	54.0	29.5	33.1	74.8	33.1	33.1	54.0	74.8	74.8
2001	2	51.8	18.8	38.6	65.1	38.6	38.6	51.8	65.1	65.1
2002	3	79.1	11.3	66.3	87.6	66.3	66.3	83.5	87.6	87.6
2003	8	54.5	10.8	37.1	74.6	37.1	48.4	55.6	58.0	74.6
2004	2	52.0	8.3	46.1	57.8	46.1	46.1	52.0	57.8	57.8
2005	8	59.6	11.7	42.1	69.6	42.1	49.1	64.5	68.9	69.6
2006	2	68.7	0.2	68.5	68.8	68.5	68.5	68.7	68.8	68.8
2007	9	61.6	15.5	37.8	82.3	37.8	48.9	63.5	71.5	82.3
2008	11	61.8	18.2	23.8	81.2	43.7	48.8	66.9	76.0	78.8
2009	12	67.2	16.0	27.9	85.0	52.2	58.7	72.3	76.9	84.9
2010	17	59.7	13.9	37.5	80.2	43.9	49.2	53.6	72.4	78.4
2011	20	61.5	14.5	34.6	79.2	39.8	45.3	67.2	71.7	76.0
2012	22	64.8	15.3	36.9	101	43.3	57.0	66.1	75.3	81.5
2013	20	65.7	11.0	42.2	86.3	51.0	59.5	66.4	74.6	78.0
1998-2013	142	62.1	14.6	23.8	101	42.3	51.1	64.9	72.9	78.7

Table 4

Age distribution by 5-year age group and gender for period 1998-2013
(incl. DCO)

Age at diagnosis Years	Cases n	%	Cum.%	Males n	%	Cum.%	Females n	%	Cum.%
15-19	1	0.3	0.3	1	0.5	0.5			0.0
20-24	1	0.3	0.6			0.5	1	0.7	0.7
25-29	6	1.8	2.4	4	2.2	2.7	2	1.4	2.1
30-34	3	0.9	3.4	1	0.5	3.2	2	1.4	3.5
35-39	11	3.4	6.7	5	2.7	5.9	6	4.2	7.7
40-44	19	5.8	12.5	8	4.3	10.2	11	7.7	15.5
45-49	25	7.6	20.1	14	7.5	17.7	11	7.7	23.2
50-54	25	7.6	27.7	16	8.6	26.3	9	6.3	29.6
55-59	33	10.1	37.8	15	8.1	34.4	18	12.7	42.3
60-64	46	14.0	51.8	35	18.8	53.2	11	7.7	50.0
65-69	57	17.4	69.2	34	18.3	71.5	23	16.2	66.2
70-74	46	14.0	83.2	25	13.4	84.9	21	14.8	81.0
75-79	37	11.3	94.5	21	11.3	96.2	16	11.3	92.3
80-84	14	4.3	98.8	7	3.8	100.0	7	4.9	97.2
85+	4	1.2	100.0			100.0	4	2.8	100.0
All ages	328	100.0		186	100.0		142	100.0	

Included in the statistics are 39.2% multiple primaries in males and 26.8% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers
for period 1998-2013

Age at diagnosis Years	Males n	Females n	Males Age-spec. incid.	Females Age-spec. incid.	Males DCO rate n=0 %	Females DCO rate n=0 %	Males Prop.all cancers n=158258 %	Females Prop.all cancers n=153136 %
0- 4			0.0	0.0				
5- 9			0.0	0.0				
10-14			0.0	0.0				
15-19	1		0.1	0.0			0.3	
20-24		1	0.0	0.1				0.2
25-29	4	2	0.2	0.1			0.4	0.2
30-34	1	2	0.0	0.1			0.1	0.1
35-39	5	6	0.2	0.3			0.2	0.2
40-44	8	11	0.3	0.4			0.2	0.2
45-49	14	11	0.6	0.5			0.3	0.1
50-54	16	9	0.8	0.4			0.2	0.1
55-59	15	18	0.8	0.9			0.1	0.1
60-64	35	11	2.0	0.6			0.2	0.1
65-69	34	23	2.2	1.3			0.1	0.1
70-74	25	21	2.0	1.4			0.1	0.1
75-79	21	16	2.5	1.3			0.1	0.1
80-84	7	7	1.4	0.8			0.1	0.0
85+		4	0.0	0.4				0.0
All ages	186	142			0.0	0.0	0.1	0.1
Incidence								
Raw			0.6	0.5				
WS			0.4	0.3				
ES			0.5	0.3				
BRD-S			0.6	0.4				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2013
MALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%		EAR	DCO %
C33-C34 Lung	3	0.6	4.7	1.0	13.6		55.6	33.3
C61 Prostate	6	1.6	3.8	1.4	8.4	#	104.7	
C64 Kidney	2	0.2	10.2	1.2	36.7	#	42.5	
Other primaries	2	0.7	2.8	0.3	10.3		30.6	
Not observed	0	2.3	0.0	0.0	1.6		-54.6	
All mult. primaries	13	5.4	2.4	1.3	4.1	#	178.9	7.7

Patients	116
Median age at second malignancy (years)	68.3
Person-years	424
Mean observation time (years)	3.7
Median observation time (years)	2.2

The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2013
FEMALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%		EAR	DCO %
C33-C34 Lung	2	0.2	12.8	1.5	46.1	#	71.5	100.0
C50 Breast	2	0.7	2.7	0.3	9.9		49.2	
Other primaries	3	0.1	22.0	4.5	64.2	#	111.0	33.3
Not observed	0	1.2	0.0	0.0	3.0		-47.4	
All mult. primaries	7	2.2	3.1	1.3	6.4	#	184.3	42.9

Patients	78
Median age at second malignancy (years)	66.4
Person-years	258
Mean observation time (years)	3.3
Median observation time (years)	2.2

The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".

P-NET: Pancreatic neuroendocrine tumor
Age distribution and age-specific incidence 1998 - 2013 (Males: 186, Females: 142)

Figure 7. Age distribution and age-specific incidence

Figure 7a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2014, based on the November 2013 submission. http://www.seer.cancer.gov.

P-NET: Pancreatic neuroendocrine tumor

Cumulative follow-up years since diagnosis for period 1998 - 2013 (excl. DCO)

Gender	n	Target		Actual	
		Sum	Median	Sum	Median
All patients					
Males	109	471	3.1	443	2.7
Females	77	286	2.9	281	2.9
Patients alive					
Males	60	373	6.2	345	5.8
Females	57	241	3.1	236	3.1

Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.

Average incidence (world standard population) 2007 - 2013: Males

Average incidence (world standard population) 2007 - 2013: Females

Figure 9a. Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.5/100,000 WS N=122, females 0.4/100,000 WS N=111).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,928 female residents (averaged) in the period from 2007 to 2013 a total of 1 women were identified with newly diagnosed pancr. neuroend. tumor. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.1/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.1/100,000.

Standardized incidence ratio (SIR) 2007 - 2013: Males

Standardized incidence ratio (SIR) 2007 - 2013: Females

Figure 9b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=122, females N=111).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,642 female residents (averaged) in the period from 2007 to 2013 a total of 1 women were identified with newly diagnosed pancr. neuroend. tumor. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.33. Though, the value of this parameter may vary with an underlying probability of 99% between 0.00 and 2.43, and is therefore not statistically striking.

MORTALITY

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status,
proportion of DCO, deaths among the annual cohorts,
and proportion of available death certificates
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.64 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	9	100.0	7	77.8	85.7
1999	7	85.7	3	42.9	100.0
2000	5	100.0	3	60.0	100.0
2001	4	100.0	2	50.0	100.0
2002	13	100.0	9	69.2	88.9
2003	14	92.9	9	64.3	100.0
2004	11	100.0	7	63.6	100.0
2005	18	100.0	9	50.0	100.0
2006	14	100.0	9	64.3	100.0
2007	26	88.5	12	46.2	100.0
2008	18	83.3	7	38.9	100.0
2009	26	96.2	19	73.1	94.7
2010	39	71.8	18	46.2	94.4
2011	42	64.3	14	33.3	100.0
2012	48	68.8	8	16.7	87.5
2013	34	100.0	7	20.6	100.0
1998-2013	328	84.8	143	43.6	96.5

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates
and cases deceased the same year of cancer diagnosis
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.64 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	9	2	50.0	1	11.1
1999	7	6	100.0	2	28.6
2000	5	3	100.0	1	20.0
2001	4	3	100.0		
2002	13	6	100.0	1	7.7
2003	14	7	100.0	2	14.3
2004	11	6	100.0	1	9.1
2005	18	6	100.0	3	16.7
2006	14	7	100.0	2	14.3
2007	26	14	100.0	4	15.4
2008	18	9	100.0	1	5.6
2009	26	12	91.7	7	26.9
2010	39	17	94.1	3	7.7
2011	42	17	100.0	5	11.9
2012	48	16	100.0	5	10.4
2013	34	24	95.8	5	14.7
1998-2013	328	155	97.4	43	13.1

Table 10c

Annual cohorts of deaths, proportion of cancer-related and non-cancer-
related deaths, and cancer recorded on death certificates
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.64 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer-related %	Prop. non-cancer-related %	Prop. cancer recorded on death certificate %
1998	2	100.0		100.0
1999	6	100.0		100.0
2000	3	100.0		100.0
2001	3	100.0		100.0
2002	6	100.0		83.3
2003	7	100.0		100.0
2004	6	83.3	16.7	83.3
2005	6	100.0		100.0
2006	7	100.0		100.0
2007	14	92.9	7.1	92.9
2008	9	88.9	11.1	88.9
2009	12	83.3	16.7	90.9
2010	17	88.2	11.8	81.3
2011	17	82.4	17.6	94.1
2012	16	93.8	6.3	87.5
2013	24	91.7	8.3	91.3
1998–2013	155	91.6	8.4	91.4

Table 11a

Medians of age at death according to the grouping in Table 10
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	2	71.9	71.9		65.7
1999	6	64.3	64.3		64.3
2000	2	59.5	59.5		59.5
2001	1	64.6	64.6		64.6
2002	5	65.1	65.1		64.7
2003	4	63.9	63.9		63.9
2004	3	67.8	67.8		67.8
2005	5	70.5	70.5		70.5
2006	7	66.5	66.5		66.5
2007	6	61.5	61.5		61.5
2008	6	58.1	58.1		58.1
2009	5	54.4	58.3	43.5	58.3
2010	10	74.1	74.1	75.1	72.9
2011	8	68.4	68.4		68.4
2012	11	64.7	65.2	59.7	64.7
2013	16	72.9	72.1	81.4	72.3
1998–2013	97	66.5	66.5	71.6	65.7

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b

Medians of age at death according to the grouping in Table 10
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998					
1999					
2000	1	54.7	54.7		54.7
2001	2	69.9	69.9		69.9
2002	1	66.4	66.4		66.4
2003	3	36.4	36.4		36.4
2004	3	62.5	54.8	65.9	54.8
2005	1	90.8	90.8		90.8
2006					
2007	8	70.2	71.0	48.9	71.0
2008	3	78.9	71.5	81.8	71.5
2009	7	72.2	62.6	86.8	62.6
2010	7	68.2	68.2		68.8
2011	9	72.4	67.7	74.4	73.4
2012	5	58.5	58.5		58.5
2013	8	65.4	65.4		66.1
1998–2013	58	66.3	66.1	74.4	67.9

By 2010, life expectancy for a newborn male in Germany is 77.5 years compared with 82.6 years for his female counterpart.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	2	0.2	0.33	0.1	0.34	0.2	0.38	0.2	0.44
1999	6	0.5	1.00	0.3	0.87	0.4	0.88	0.5	0.86
2000	2	0.2	0.67	0.1	0.75	0.2	0.71	0.2	0.67
2001	1	0.1	0.50	0.0	0.50	0.1	0.50	0.1	0.50
2002	5	0.3	0.50	0.2	0.43	0.2	0.44	0.2	0.45
2003	4	0.2	0.67	0.1	0.63	0.2	0.65	0.2	0.69
2004	3	0.2	0.33	0.1	0.30	0.1	0.33	0.2	0.35
2005	5	0.3	0.50	0.1	0.43	0.2	0.47	0.3	0.53
2006	7	0.4	0.58	0.2	0.40	0.3	0.48	0.3	0.53
2007	6	0.3	0.35	0.2	0.32	0.2	0.34	0.3	0.41
2008	6	0.3	0.86	0.2	0.95	0.3	0.94	0.3	0.90
2009	4	0.2	0.29	0.1	0.34	0.2	0.33	0.2	0.28
2010	8	0.4	0.36	0.2	0.30	0.3	0.34	0.4	0.39
2011	8	0.4	0.36	0.2	0.31	0.3	0.32	0.3	0.35
2012	10	0.4	0.38	0.2	0.39	0.3	0.39	0.4	0.38
2013	14	0.6	1.00	0.3	0.95	0.4	0.98	0.6	0.99
1998-2013	91	0.3	0.49	0.2	0.46	0.2	0.48	0.3	0.50

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998									
1999									
2000	1	0.1	0.50	0.1	0.63	0.1	0.68	0.1	0.57
2001	2	0.2	1.00	0.1	0.87	0.1	0.98	0.2	1.11
2002	1	0.1	0.33	0.0	0.62	0.0	0.52	0.0	0.41
2003	3	0.2	0.38	0.1	0.47	0.1	0.38	0.2	0.38
2004	2	0.1	1.00	0.1	0.96	0.1	0.88	0.1	0.92
2005	1	0.1	0.13	0.0	0.04	0.0	0.06	0.0	0.08
2006									
2007	7	0.3	0.78	0.2	0.72	0.2	0.75	0.3	0.75
2008	2	0.1	0.18	0.0	0.16	0.1	0.18	0.1	0.20
2009	6	0.3	0.50	0.1	0.55	0.2	0.54	0.2	0.47
2010	7	0.3	0.41	0.2	0.43	0.2	0.40	0.3	0.41
2011	6	0.3	0.30	0.1	0.26	0.2	0.27	0.2	0.30
2012	5	0.2	0.23	0.1	0.21	0.2	0.22	0.2	0.22
2013	8	0.3	0.40	0.2	0.38	0.2	0.37	0.3	0.35
1998-2013	51	0.2	0.36	0.1	0.35	0.1	0.35	0.1	0.35

Table 13

Age distribution of age at death (cancer-related) for period 1998-2013
(**incl. multiple primaries**)

Age at death Years	Cases n	%	Cum.%	Males n	%	Cum.%	Females n	%	Cum.%
15-19	1	0.7	0.7	1	1.1	1.1			0.0
20-24	0	0.0	0.7			1.1			0.0
25-29	2	1.4	2.1			1.1	2	3.9	3.9
30-34	0	0.0	2.1			1.1			3.9
35-39	3	2.1	4.2	2	2.2	3.3	1	2.0	5.9
40-44	4	2.8	7.0	1	1.1	4.4	3	5.9	11.8
45-49	6	4.2	11.3	1	1.1	5.5	5	9.8	21.6
50-54	14	9.9	21.1	8	8.8	14.3	6	11.8	33.3
55-59	11	7.7	28.9	7	7.7	22.0	4	7.8	41.2
60-64	22	15.5	44.4	18	19.8	41.8	4	7.8	49.0
65-69	26	18.3	62.7	20	22.0	63.7	6	11.8	60.8
70-74	20	14.1	76.8	12	13.2	76.9	8	15.7	76.5
75-79	16	11.3	88.0	12	13.2	90.1	4	7.8	84.3
80-84	11	7.7	95.8	8	8.8	98.9	3	5.9	90.2
85+	6	4.2	100.0	1	1.1	100.0	5	9.8	100.0
All ages	142	100.0		91	100.0		51	100.0	

Included in the statistics are 39.2% multiple primaries in males and 26.8% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2013
(**incl. multiple primaries**)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19	1		0.1	1.00	0.0		2.2	
20-24			0.0		0.0			
25-29		2	0.0		0.1	1.00		1.7
30-34			0.0		0.0			
35-39	2	1	0.1	0.40	0.0	0.17	0.5	0.2
40-44	1	3	0.0	0.13	0.1	0.27	0.1	0.3
45-49	1	5	0.0	0.07	0.2	0.45	0.1	0.2
50-54	8	6	0.4	0.50	0.3	0.67	0.2	0.2
55-59	7	4	0.4	0.47	0.2	0.22	0.1	0.1
60-64	18	4	1.0	0.51	0.2	0.36	0.2	0.1
65-69	20	6	1.3	0.59	0.3	0.26	0.2	0.1
70-74	12	8	0.9	0.48	0.5	0.38	0.1	0.1
75-79	12	4	1.5	0.57	0.3	0.25	0.1	0.0
80-84	8	3	1.6	1.14	0.3	0.43	0.1	0.0
85+	1	5	0.3	1.00	0.6	1.25	0.0	0.0
All ages	91	51					0.1	0.1

```
Mortality
  Raw            0.3   0.49   0.2   0.36
  WS             0.2   0.46   0.1   0.35
  ES             0.2   0.48   0.1   0.35
  BRD-S          0.3   0.50   0.1   0.35

PYLL-70
  per 100,000    2.2          1.9
  ES             2.0          1.7
AYLL-70         10.0         16.5
```

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a

Multiple primaries in deaths in period 1998-2013
MALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C12-C13 Hypopharynx	1	2.9	1	100.0				
C16 Stomach	5	14.3	4	80.0			1	20.0
C18 Colon	3	8.6	1	33.3	2	66.7		
C19-C20 Rectum	2	5.7			1	50.0	1	50.0
C23-C24 Bile	1	2.9	1	100.0				
C25 Pancreas	1	2.9			1	100.0		
C33-C34 Lung	2	5.7	1	50.0			1	50.0
C43 Malign. melanoma	3	8.6	2	66.7	1	33.3		
C44 Skin others	2	5.7	2	100.0				
C61 Prostate	8	22.9	6	75.0			2	25.0
C64 Kidney	2	5.7	2	100.0				
C67 Bladder	1	2.9	1	100.0				
C70-C72 CNS cancer	2	5.7					2	100.0
C73 Thyroid	1	2.9	1	100.0				
C91-C96 Leukaemia	1	2.9	1	100.0				
All mult. primaries	35	100.0	23	65.7	5	14.3	7	20.0

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 15b

Multiple primaries in deaths in period 1998-2013
FEMALES

Diagnosis		Total n	Total %↓	Pre n	Pre ←%	Syn-chron ±30d n	Syn-chron ±30d ←%	Post n	Post ←%
C16	Stomach	1	9.1					1	100.0
C23-C24	Bile	1	9.1			1	100.0		
C25	Pancreas	1	9.1			1	100.0		
C33-C34	Lung	4	36.4	1	25.0			3	75.0
C50	Breast	2	18.2	1	50.0			1	50.0
C70-C72	CNS cancer	1	9.1			1	100.0		
C73	Thyroid	1	9.1	1	100.0				
All mult. primaries		11	100.0	3	27.3	3	27.3	5	45.5

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2013
(**Singular primaries only ***)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19	1		0.1	1.00	0.0		2.4	
20-24			0.0		0.0			
25-29		2	0.0		0.1	1.00		1.8
30-34			0.0		0.0			
35-39	2	1	0.1	0.40	0.0	0.17	0.5	0.2
40-44	1	3	0.0	0.14	0.1	0.30	0.1	0.3
45-49	1	3	0.0	0.08	0.1	0.30	0.1	0.2
50-54	8	6	0.4	0.50	0.3	0.75	0.3	0.2
55-59	5	3	0.3	0.45	0.2	0.21	0.1	0.1
60-64	15	4	0.8	0.54	0.2	0.44	0.2	0.1
65-69	16	6	1.0	0.67	0.3	0.29	0.2	0.1
70-74	7	8	0.5	0.44	0.5	0.47	0.1	0.1
75-79	5	3	0.6	0.42	0.3	0.25	0.1	0.0
80-84	8	3	1.6	1.33	0.3	0.75	0.1	0.0
85+	1	3	0.3	1.00	0.3	1.50	0.0	0.0
All ages	70	45					0.1	0.1
Mortality								
Raw			0.2	0.49	0.1	0.38		
WS			0.1	0.45	0.1	0.37		
ES			0.2	0.48	0.1	0.37		
BRD-S			0.2	0.50	0.1	0.37		
PYLL-70								
per 100,000			2.0		1.7			
ES			1.8		1.5			
AYLL-70			10.7		16.3			

* See corresponding tables with multiple primaries.

Table 17

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2013
(**Single primaries only ***)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19	1		0.1	1.00	0.0		2.4	
20-24			0.0		0.0			
25-29		2	0.0		0.1	1.00		1.9
30-34			0.0		0.0			
35-39	2	1	0.1	0.40	0.0	0.25	0.6	0.2
40-44	1	2	0.0	0.14	0.1	0.20	0.1	0.2
45-49	1	2	0.0	0.10	0.1	0.22	0.1	0.1
50-54	8	6	0.4	0.53	0.3	0.75	0.3	0.3
55-59	5	3	0.3	0.45	0.2	0.21	0.1	0.1
60-64	14	4	0.8	0.58	0.2	0.50	0.2	0.1
65-69	15	4	1.0	0.68	0.2	0.21	0.2	0.1
70-74	6	8	0.5	0.40	0.5	0.50	0.1	0.1
75-79	5	3	0.6	0.50	0.3	0.25	0.1	0.0
80-84	7	3	1.4	1.17	0.3	1.00	0.1	0.0
85+	1	2	0.3	1.00	0.2	1.00	0.0	0.0
All ages	66	40					0.1	0.1
Mortality								
Raw			0.2	0.50	0.1	0.36		
WS			0.1	0.47	0.1	0.35		
ES			0.2	0.49	0.1	0.35		
BRD-S			0.2	0.51	0.1	0.36		
PYLL-70								
per 100,000			1.9		1.5			
ES			1.8		1.4			
AYLL-70			10.9		16.7			

* See corresponding tables with multiple primaries.

P-NET: Pancreatic neuroendocrine tumor
Age distribution and age-specific mortality 1998 - 2013 (Males: 91, Females: 51)

Figure 18. Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at pancr. neuroend. tumor-related death (see Table 10) should be considered.

Average mortality (world standard population) 2007 - 2013: Males

Average mortality (world standard population) 2007 - 2013: Females

Figure 19a. Map of cancer mortality (world standard population) by county averaged for period 2007 to 2013. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.2/100,000 WS N=55, females 0.1/100,000 WS N=40).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,928 female residents (averaged) in the period from 2007 to 2013 a total of 0 women died from pancr. neuroend. tumor. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.0/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.2/100,000.

Standardized mortality ratio (SMR) 2007 - 2013: Males

Standardized mortality ratio (SMR) 2007 - 2013: Females

Figure 19b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2007 to 2013. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=55, females N=40).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 64,642 female residents (averaged) in the period from 2007 to 2013 a total of 0 women died from pancr. neuroend. tumor. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.00. Though, the value of this parameter may vary with an underlying probability of 99% between 0.00 and 4.89, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. **All multiple primaries included**

   The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. **First singular primary** (no information about other prior or synchronous malignancy)

   The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. **Single primary** (no information about other prior, syn- or metachronous malignancy)

   The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

FRG	Federal Republic of Germany
GEKID	Association of Population-based Cancer Registries in Germany
	(Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
MCR	Munich Cancer Registry (Tumorregister München)
SEER	Surveillance, Epidemiology, and End Results (USA)

AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
BRD-S	German standard population
DCO	Death certificate only
EAR	Excess absolute risk
	= excess cancer cases (O - E) per 10,000 person-years
ES	European standard population (old)
LCL	Lower confidence limit
MI-index	Ratio between mortality and incidence
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
SIR	Standardized incidence ratio
SMR	Standardized mortality ratio
UCL	Upper confidence limit
WS	World standard population

Recommended Citation

Munich Cancer Registry. Baseline statistics P-NET: Pancr. neuroend. tumor [Internet]. 2015 [updated 2015 May 19; cited 2015 Jul 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base_hPNETE.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables